CD3D Specific Neutra™ Antibody Products

CD3 (cluster of differentiation 3) is a protein complex and T cell co-receptor (TCR) that partakes in the activation of the cytotoxic T cell and T helper cells (CD8⁺ naive T cells and CD4⁺ naive T cells). CD3 contains four chains, which belong to the immunoglobulin superfamily and all have immunoreceptor tyrosine-based stimulation motifs in their cytoplasmic structural domains.

CD3D (CD3D molecule, CD3δ), is one of the CD3 chains and also participates in signal transduction of T-cell development.

Fig.1 CD3 structure and T cell activation pathway.¹

Its Gene ID: 915, UniProtKB ID: P04234, and OMIM ID: 186790.

Functions of CD3D

TCR/CD3 complex is an essential modulator of peripheral T lymphocytes. Evidence from previous studies has shown that CD3D is significantly associated with the occurrence, development, and immune microenvironment of tumors, as well as the effect and prognosis of treatment. It is reported that CD3D is closely involved with PD1 and can be applied to predict the responses to immunochemotherapy in diffuse large B-cell lymphoma. Besides, it is also demonstrated that CD3D expression can decrease the prognostic risk of bladder cancer. In head and neck squamous cell carcinoma (HNSCC), CD3D is reported to participate in immune cell infiltration and immune-related signaling, emerging as a potential independent prognostic biomarker of HNSCC.

CD3D as a Target for Monoclonal Antibody Development

Considering the critical roles of CD3D in various immune responses involved with a wide range of diseases, antibodies targeting CD3D can be very useful tools to study its interactions with many other regulatory molecules that remain to be explored, thus clarifying detailed mechanisms and guide the directions for related development of therapeutics. CD3D can also serve as a prognostic indicator in a variety of diseases (including several types of tumors, septic shock, rheumatoid arthritis, etc.), and a drug target in cancer research.

Creative Biolabs offers various recombinant anti-CD3D (N-terminus) antibody products. These antibodies are recombinantly expressed and could be used for various purposes. Customization of CD3D-based monoclonal antibodies or neutralizing antibodies is also available for you here.

REFERENCE

1. Menon, Ashwathi Puravankara, et al. "Modulating T cell responses by targeting CD3." Cancers 15.4 (2023): 1189.